Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-002534-20 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate BMS-986165 in participants with different levels of liver function.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Normal liver function | Experimental | Single dose |
|
| Mild liver impairment | Experimental | Single dose |
|
| Moderate liver impairment | Experimental | Single dose |
|
| Severe liver impairment | Experimental | Single dose |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-986165 | Drug | Oral administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum observed plasma concentration (Cmax) | Approximately 9 days | |
| Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] | Approximately 9 days | |
| Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] | Approximately 9 days |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation | Approximately 44 days | |
| Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations | Approximately 44 days |
Not provided
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pharmaceutical Research Associates CZ, s.r.o | Prague | 170 00 | Czechia | |||
| Kenezy Gyula Korhaz es Rendelointezet |
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trial Information | View source |
| BMS Clinical Trial Patient Recruiting | View source |
| Investigator Inquiry Form |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Debrecen |
| 4043 |
| Hungary |
| Clinical Research Unit Hungary | Miskolc | 3529 | Hungary |
| Local Institution | Bratislava | 831 01 | Slovakia |
| FDA Safety Alerts and Recalls | View source |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| ID | Term |
|---|---|
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000628674 | deucravacitinib |
Not provided
Not provided
Not provided